ArticleOpen life sciences2026
Effects of luteolin on proliferation and apoptosis of breast cancer cells by regulating EGFR/STAT3/AKt pathway.
Article in Open life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) is a common malignant tumor in women, characterized by high recurrence rates, a significant risk of metastasis, and limitations of existing treatments. The anticancer activity of the natural compound luteolin (LU) has been confirmed, but its specific mechanism of action in breast cancer cells (BCCs) has not been fully elucidated. This study aimed to investigate the effects of LU on the proliferation and apoptosis of BCCs and to clarify its association with the epidermal growth factor receptor (EGFR)/signal transducer and activator of transcription 3 (STAT3)/protein kinase B (Akt) pathway. Using MCF-7 breast cancer cells as the research subject, experimental groups were set up with 5, 15, 25, 35, and 45 μmol/L LU treatment and a dimethyl sulfoxide (DMSO) solvent control group. Cell proliferation activity, reactive oxygen species (ROS) levels, apoptosis rate (AR), and the expression of phosphorylated Akt (p-Akt), phosphorylated EGFR (p-EGFR), and phosphorylated STAT3 (p-STAT3) were detected. LU at concentrations of 25, 35, and 45 μmol/L significantly inhibited the proliferation of MCF-7 cells (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.